File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: gdT cells stimulated by a novel vaccine confer protection to the naïve mice against S. aureus challenge

TitlegdT cells stimulated by a novel vaccine confer protection to the naïve mice against S. aureus challenge
Authors
Issue Date2020
PublisherAmerican Association of Immunologists. The Journal's web site is located at http://www.jimmunol.org
Citation
The 2020 Annual Meeting of The American Association of Immunologists (IMMUNOLOGY2020™), May 2020. Abstracts in The Journal of Immunology, 2020, v. 204 n. 1, Suppl., abstract no. 168.16 How to Cite?
AbstractStaphylococcus aureus (S. aureus) is a common pathogen found in the community and in hospitals. Most notably, Methicillin-resistant S. aureus is resistant to many antibiotics, which is a growing public health concern. The emergence of drug-resistant strains has prompted the search for alternative treatments such as immunotherapeutic approaches. Prophylactic vaccination is the best approach to combat against MRSA since it can provide protection without any concerns regarding antibiotic resistance. To date, most clinical trials of vaccines or passive immunization against S. aureus have ended in failure. In this study, we investigated multiple proteins as possible targets for a vaccine. Mice vaccinated with these purified proteins elicited high titers of specific antibodies as well as Th1- and Th17-biased immune responses in mice. Animal test indicated a protection rate over 90% in several animal models against multiple strains of S. aureus. Interestingly, gdT cells transferred from the vaccinated mice to naïve mice can confer protection to the naïve mice against S. aureus challenge in skin infection models. These findings raise the hope that the candidate antigens could be developed into multivalent and serotype-independent vaccines against S. aureus infection. Copyright © 2020 by The American Association of Immunologists, Inc.
DescriptionSession: 168. Vaccines against Bacteria and Parasites - no. 168.16; Board Number: P1280
IMMUNOLOGY2020™ which was scheduled to take place May 8 – 12 in Honolulu, Hawai’i was cancelled due to COVID-19
Persistent Identifierhttp://hdl.handle.net/10722/305751
ISSN
2023 Impact Factor: 3.6
2023 SCImago Journal Rankings: 1.558

 

DC FieldValueLanguage
dc.contributor.authorHuang, J-
dc.contributor.authorWang, X-
dc.contributor.authorZhang, B-
dc.contributor.authorDeng, J-
dc.contributor.authorYuen, KY-
dc.date.accessioned2021-10-20T10:13:48Z-
dc.date.available2021-10-20T10:13:48Z-
dc.date.issued2020-
dc.identifier.citationThe 2020 Annual Meeting of The American Association of Immunologists (IMMUNOLOGY2020™), May 2020. Abstracts in The Journal of Immunology, 2020, v. 204 n. 1, Suppl., abstract no. 168.16-
dc.identifier.issn0022-1767-
dc.identifier.urihttp://hdl.handle.net/10722/305751-
dc.descriptionSession: 168. Vaccines against Bacteria and Parasites - no. 168.16; Board Number: P1280-
dc.descriptionIMMUNOLOGY2020™ which was scheduled to take place May 8 – 12 in Honolulu, Hawai’i was cancelled due to COVID-19-
dc.description.abstractStaphylococcus aureus (S. aureus) is a common pathogen found in the community and in hospitals. Most notably, Methicillin-resistant S. aureus is resistant to many antibiotics, which is a growing public health concern. The emergence of drug-resistant strains has prompted the search for alternative treatments such as immunotherapeutic approaches. Prophylactic vaccination is the best approach to combat against MRSA since it can provide protection without any concerns regarding antibiotic resistance. To date, most clinical trials of vaccines or passive immunization against S. aureus have ended in failure. In this study, we investigated multiple proteins as possible targets for a vaccine. Mice vaccinated with these purified proteins elicited high titers of specific antibodies as well as Th1- and Th17-biased immune responses in mice. Animal test indicated a protection rate over 90% in several animal models against multiple strains of S. aureus. Interestingly, gdT cells transferred from the vaccinated mice to naïve mice can confer protection to the naïve mice against S. aureus challenge in skin infection models. These findings raise the hope that the candidate antigens could be developed into multivalent and serotype-independent vaccines against S. aureus infection. Copyright © 2020 by The American Association of Immunologists, Inc.-
dc.languageeng-
dc.publisherAmerican Association of Immunologists. The Journal's web site is located at http://www.jimmunol.org-
dc.relation.ispartofJournal of Immunology-
dc.relation.ispartofAmerican Association of Immunologists (AAI) 2020 Annual Meeting (IMMUNOLOGY2020™)-
dc.titlegdT cells stimulated by a novel vaccine confer protection to the naïve mice against S. aureus challenge-
dc.typeConference_Paper-
dc.identifier.emailHuang, J: jdhuang@hku.hk-
dc.identifier.emailWang, X: xiaoleiw@hku.hk-
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.authorityHuang, J=rp00451-
dc.identifier.authorityYuen, KY=rp00366-
dc.description.natureabstract-
dc.identifier.hkuros326884-
dc.identifier.volume204-
dc.identifier.issue1, Suppl.-
dc.identifier.spageabstract no. 168.16-
dc.identifier.epageabstract no. 168.16-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats